Biopharmaceuticals Market: How Is the Commercial Biosimilar Erosion of Blockbuster Biopharmaceutical Revenue Creating Strategic Portfolio Repositioning?
Blockbuster biopharmaceutical patent cliff commercial impact — the commercial revenue erosion that biosimilar competition creates when major biopharmaceutical patents expire — exemplified by Humira's (adalimumab) commercial revenue decline from USD 21.2 billion peak to dramatically lower post-biosimilar launch levels as Amjevita, Hadlima, Cyltezo, Hyrimoz, and multiple additional...
0 التعليقات 0 المشاركات 39 مشاهدة 0 معاينة
إعلان مُمول